RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome
NCT ID: NCT03684564
Last Updated: 2023-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
43 participants
INTERVENTIONAL
2021-07-09
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
40 patients will be randomised with a ratio of 1:1 to receive either:
* Rivaroxaban 15mg twice daily orally for 24 months or
* Warfarin (standard of care in the RISAPS trial) to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months.
The primary outcome of the trial is the rate of change in brain white matter hyperintensity (WMH) volume between baseline and 24 months follow up, assessed on brain magnetic resonance imaging (MRI), a surrogate marker of ischaemic damage.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently, APS patients who have had an ischaemic stroke (which occurs when blood flow to an area of brain is cut off) are treated with warfarin to reduce the risk of a recurrence. Warfarin tends to have a variable 'blood thinning' effect in patients with APS, necessitating frequent (usually weekly) INR blood tests to monitor the effect of the warfarin, which is inconvenient for patients.
The RISAPS trial will compare higher intensity (higher dose) rivaroxaban versus higher intensity warfarin (current standard of care treatment) for 24 months, in APS patients, with or without lupus (systemic lupus erythematosus; SLE), requiring higher intensity anticoagulation after experiencing a stroke, a 'mini stroke' (also known as a transient ischaemic attack) or other ischaemic brain damage (caused by blood clots in the brain arteries or smaller blood vessels). When compared with warfarin, a dvantages of rivaroxaban include, fixed dose prescribing and no need for monitoring of anticoagulant effect.
Furthermore, rivaroxaban has fewer drug-food interactions, and significantly fewer drug-drug interactions than warfarin. If rivaroxaban is no worse than warfarin for anticoagulation of APS patients with stroke or other ischaemic brain manifestations, it could become the standard of care for the treatment of APS patients, with or without lupus, who have experienced stroke or other ischaemic brain manifestations and improve patients' quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rivaroxaban (Treatment Arm)
Rivaroxaban
Oral tablet 15 mg twice daily for 24 months
Warfarin (Control Arm)
Warfarin
Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rivaroxaban
Oral tablet 15 mg twice daily for 24 months
Warfarin
Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
3. Patients must weigh ≥ 50kg and ≤ 135kg.
4. Women must be on adequate contraception, barrier or hormonal, unless postmenopausal or sterilised.
1. Patients who are triple positive for antiphospholipid antibodies (presence of lupus anticoagulant, IgG and/or IgM anticardiolipin and anti beta 2 glycoprotein I antibodies at \>40 GPL or MPL units or \> the 99th centile of normal\*.
(\*patients who have previously been triple aPL-positive and have single or double aPL positivity on at least 2 occasions over at least 6 months, including once within 1 month prior to randomisation, can be recruited to the trial)
2. Pregnant or lactating women
3. Severe renal impairment with creatinine clearance \< 30 mL/min (i.e. 29 mL/min or less)
4. Liver function tests ALT \> 3 x ULN
5. Cirrhotic patients with Child Pugh B or C
6. Thrombocytopenia (platelets \< 75 x 109/L)
7. Non-adherence on warfarin (based on clinical assessment)
8. Patients taking strong inhibitors of both CYP3A4 and P-gp pathways such as
1. Systemic azole antifungals (e.g. ketoconazole, itraconazole, voriconazole, posaconazole)
2. Patients on human immunodeficiency virus (HIV) protease inhibitors (e.g. ritonavir)
9. Patients on strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital or St. John's Wort)
10. Patients on dronedarone
11. Patients on levetiracetam, sodium valproate/valproic acid, oxcarbazepine or topiramate
12. Patients less than 18 years of age
13. Refusal to consent to the site informing General Practitioner (GP) and Healthcare Professional responsible for anticoagulation care of the participant.
14. Contraindications to MRI (e.g. cardiac pacemaker, severe claustrophobia, inability to lie flat: patients who do not meet local safety rules for MRI).
15. Patients at high risk of bleeding and not suitable for anticoagulation therapy.
16. Previous known allergy or intolerance to warfarin or rivaroxaban.
17. Women planning to become pregnant within the 2-year follow-up period.
18. Patients with known galactose intolerance, total lactase deficiency or galactose malabsorption.
19. Patients who have had active cancer (excluding non-melanoma skin cancers) within the last 2 years
20. Any other reason that the PI or delegate considers would make the patient unsuitable to enter RISAPS.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College London Hospitals
OTHER
Barking, Havering and Redbridge University Hospitals NHS Trust
OTHER
Hammersmith Hospitals NHS Trust
OTHER
Epsom and St Helier University Hospitals NHS Trust
OTHER
Barts & The London NHS Trust
OTHER
King's College Hospital NHS Trust
OTHER
Versus Arthritis (Funder)
UNKNOWN
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hannah Cohen
Role: PRINCIPAL_INVESTIGATOR
University College London Hospitals NHS Foundation Trust/University College London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Epsom and St Helier University Hospitals NHS Trust
Epsom, , United Kingdom
Barts and the London Hospitals, Barts Health NHS Trust
London, , United Kingdom
Hammersmith Hospital, Imperial College Healthcare NHS Trust
London, , United Kingdom
Kings College Hospital NHS Foundation Trust
London, , United Kingdom
University College Hospitals NHS Foundation Trust
London, , United Kingdom
Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust
Romford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTU/2015/174
Identifier Type: -
Identifier Source: org_study_id